

CD47 antigen inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/C02BD1580ACFEN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: C02BD1580ACFEN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "CD47 antigen inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 28+ companies and 28+ pipeline drugs in CD47 antigen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

CD47 antigen inhibitors Understanding

CD47 antigen inhibitors: Overview

CD47 (also known as the integrin-associated signal transducer) is a cell surface molecule in the immunoglobulin superfamily that has been reported to bind to several different proteins, including integrins, thrombospondin-1, and most importantly, signal regulatory protein ? (SIRP?), which is a heavily glycosylated transmembrane protein with an immunoreceptor tyrosine-based inhibition motif (ITIM). CD47 occurs in all cells, including platelets. It is an unusual member of the Ig superfamily with a V-like extracellular domain, five membrane-spanning domains, and a short cytoplasmic domain. CD47 inhibition leads to stimulation of phagocytosis of cancer cells by macrophages. Anti-CD47 antibodies enhance the phagocytosis of tumor cells by macrophages by directly blocking the binding of tumor cell-expressing CD47 to

macrophage-expressing SIRP?

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CD47 antigen inhibitors R&D. The therapies under development are focused on novel approaches for CD47 antigen inhibitors.

CD47 antigen inhibitors Emerging Drugs Chapters

This segment of the CD47 antigen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CD47 antigen inhibitors Emerging Drugs

Magrolimab: Forty Seven, Inc.

Magrolimab is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages, thus blocking the 'don't eat me' signal used by cancer cells to avoid being ingested by macrophages. Forty Seven is initially developing magrolimab, an investigational medicine, for the treatment of patients with MDS, AML, non-Hodgkin's lymphoma, ovarian cancer and colorectal carcinoma. Magrolimab has been granted Fast Track designation by the FDA for the treatment of MDS and AML, and for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, two forms of B-cell non-Hodgkin's lymphoma. Magrolimab has also been granted Orphan Drug designation by the FDA and European Medicines Agency for the treatment of AML.

Evorpcept: ALX Oncology

Evorpcept targets CD47 to maximize phagocytosis of cancer cells and activate the adaptive immune system. Evorpcept enhances checkpoint inhibition by activating

dendritic cells and reducing suppression by tumour-associated macrophages, and enhances targeted anti-cancer antibodies by maximising phagocytosis to selectively eliminate tumour cells. Currently, it is in Phase II stage of clinical trial evaluation to treat Squamous cell cancer.

Further product details are provided in the report.....

CD47 antigen inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different CD47 antigen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on CD47 antigen inhibitors

There are approx. 28+ key companies which are developing the CD47 antigen inhibitors. The companies which have their CD47 antigen inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Forty Seven, Inc.

Phases

DelveInsight's report covers around 28+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

CD47 antigen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CD47 antigen inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses CD47 antigen inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD47 antigen inhibitors drugs.

CD47 antigen inhibitors Report Insights

- CD47 antigen inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

CD47 antigen inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing CD47 antigen inhibitors drugs?

How many CD47 antigen inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CD47 antigen inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD47 antigen inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for CD47 antigen inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Forty Seven, Inc.

ALX Oncology

Shattuck Labs

EpicientRx

Waterstone Hanxbio

Akeso Biopharma

Trillium Therapeutics Inc.

Adagene

Arch Oncology

ImmuneOncia Therapeutics

Celgene Corporation

ImmuneOnco Biopharma

Light Chain Bioscience

Trillium Therapeutics Inc

TG Therapeutics

MORPHIEX BIOTHERAPEUTICS

KAHR Medical

I-MAb Biopharma

Centessa Pharmaceuticals

Hanmi Pharm.Co.,Ltd.

Innovent Biologics

OSE Immunotherapeutics

Biocad

ZAI LAB

EMulate Therapeutics

Alector, Inc.

Sorrento Therapeutics

Surface Oncology

QLSF Biotherapeutics

Ichnos Sciences

Key Products

Magrolimab

Evorpacept

SL 172154

RRx-001

HX 009

AK 117

TTI 622

AL008

ISB 1442

STI-6643

QL401

SRF231

SAFE CD47 NEObody

AO 176

IMC 002

ZL-1201

BCD-106

CC 90002

IMM 2505

BI 765063

IB1188

IMM 0306

NI 1801

TJC4

Ontorpacept

TG-1801

DSP107

MBT-001

Contents

Introduction

Executive Summary

CD47 antigen inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

CD47 antigen inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Magrolimab: Forty Seven, Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Evorpacept - ALX Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

STI-6643: Sorrento Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

ISB 1442: Ichnos Sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

CD47 antigen inhibitors Key Companies

CD47 antigen inhibitors Key Products

CD47 antigen inhibitors- Unmet Needs

CD47 antigen inhibitors- Market Drivers and Barriers

CD47 antigen inhibitors- Future Perspectives and Conclusion

CD47 antigen inhibitors Analyst Views

CD47 antigen inhibitors Key Companies

Appendix

I would like to order

Product name: CD47 antigen inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/C02BD1580ACFEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C02BD1580ACFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970